ABSTRACT: This review focuses on the construction and application of structural chemokine receptor models for the elucidation of molecular determinants of chemokine receptor modulation and the structure-based discovery and design of chemokine receptor ligands. A comparative analysis of ligand binding pockets in chemokine receptors is presented, including a detailed description of the CXCR4, CCR2, CCR5, CCR9, and US28 X-ray structures, and their implication for modeling molecular interactions of chemokine receptors with small-molecule ligands, peptide ligands, and large antibodies and chemokines. These studies demonstrate how the integration of new structural information on chemokine receptors with extensive structure−activity relationship and site-directed mutagenesis data facilitates the prediction of the structure of chemokine receptor−ligand complexes that have not been crystallized. Finally, a review of structure-based ligand discovery and design studies based on chemokine receptor crystal structures and homology models illustrates the possibilities and challenges to find novel ligands for chemokine receptors.
INTRODUCTION
Chemokines and chemokine receptors play an important role in the immune defense system by controlling the migration, activation, differentiation, and survival of leukocytes.
1,2 The 50 human chemokines are divided into C, CC, CXC, and CX3C classes based on the number and spacing of conserved cysteine residues in their N-terminus region. Chemokine receptors belong to the family A of G-protein coupled receptors (GPCRs), characterized by a seven transmembrane (7TM) helical domain ( Figure 1 ). There are 18 human chemokine receptors that are primarily activated by different subfamilies of chemokines: C (XCR1), CC (CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10), CXC (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6), or CX 3 C (CX 3 CR1), and four atypical decoy chemokine receptors (ACKRs: ACKR1, ACKR2, ACKR3/CXCR7, and ACKR4). 3 Chemokine receptors are considered to interact with their chemokine ligands via a two-step binding mechanism in which: (i) the structured C-terminal region of the chemokine first binds the N-terminus region and extracellular loops (ECLs) of the receptor (chemokine recognition site 1, CRS1), allowing (ii) the unstructured N-terminus of the chemokine to target the 7TM helical bundle (chemokine recognition site 2, CRS2) and stabilize the receptor in an active conformation that facilitates intracellular signal transduction by, e.g., G-proteins or arrestins. 1, 4 Because of their crucial role in cell migration chemokine receptors are important therapeutic targets for inflammatory diseases and cancer. 5, 6 Herpesviruses contain DNA that encodes for receptors that are similar to human chemokine receptors, including ORF74, BILF1, and US28, to hijack chemokine receptor-mediated cellular signaling networks of the host. 7 Hence, these viral chemokine receptors can therefore be considered as promising antiviral drug targets as well. 8 A variety of proteins, peptides, and small-molecule ligands have been identified that can modulate the activity of chemokine receptors 1 by targeting the minor or major pockets in the 7TM helical bundle or intracellular binding pocket (Figures 1−2) . Examples of small nonpeptide ligands are the clinically approved drugs 16 (Maraviroc, CCR5 antagonist, Figures 3 and 11) 9 and 1 (plerixafor/AMD3100, CXCR4 antagonist, Figure 11 ), 10 used for the treatment of HIV and stem cell mobilization, respectively. Molecular pharmacological, medicinal chemistry, and molecular modeling studies have provided insights into molecular PDB 3ODU; 11 pink spheres), CVX15 (PDB 3OE0; 11 cyan spheres), and (b) vMIP-II (PDB 4RWS; 13 dark-green cartoon and spheres) bound CXCR4 crystal structures. The receptor is colored for a better interpretation: 3ODU in light yellow, 3OE0 in gray. TM helices align well in the three different reported structures with subtle differences: TM1 is one turn longer (R30 N-ter 
−N33
N-ter ) and laterally shifted outward in the vMIP-II bound CXCR4 structure, TM6 is half turn shorter in the 31 bound CXCR4 structure (H232 6 .28 −Q233 6.29 ), helix 8 is missing in all the structures, and the C-terminus has only been solved for the 31 bound CXCR4 structure (A307 C-ter − S319 C-ter ). vMIP-II targets both the chemokine recognition site 1 (CRS1, comprising the N-terminus and extracellular loops of the receptor) and the chemokine recognition site 2 (CRS2, including the TM domain binding site) of CXCR4, consistent with the two-step binding model. (c) An active conformation of US28, a viral chemokine-like receptor, binding the human CX3CL1 chemokine in the extracellular binding site, and a nanobody (Nb7, purple cartoon) in the intracellular binding site (PDB 4XT1; 14 green cartoon and spheres). Both chemokines vMIP-II (a) and CX3CL1 (c) are shown as spheres on their N-terminus coils, and their globular cores are shown as a cartoon for a better visualization of their secondary structure. (d) CCR5 crystal structure bound to the small ligand 16 (PDB 4MBS; 12 magenta spheres), occupying both the transmembrane site 1 (TMS1), also known as small pocket, and transmembrane site 2 (TMS2), or major pocket. (e) CCR9 crystal structure bound to the small allosteric antagonist 30 (PDB 5LWE, 16 darkcyan spheres) targeting an intracellular allosteric intracellular pocket and thereby blocking G-protein coupling. (f) CCR2 crystal structure bound to the orthosteric antagonist 58 (orange spheres) and the allosteric antagonist 29 (lime spheres) targeting an intracellular binding pocket (PDB 5T1A to validate and improve chemokine receptor homology modeling studies, 20 to rationalize SAR data 21, 22 and to perform structurebased virtual screening and ligand design studies. 23−30 Chemokine homology models and de novo receptor models have already been successfully used to identify new ligands for CCR3, 31 CCR4, 32, 33 CCR5, 34, 35 CXCR3, 26 CXCR4, 24, [26] [27] [28] [29] [30] 36, 37 and CXCR7, 38 and the recently released crystal structures have increased the possibilities to study and predict structural chemokine receptor−ligand interactions. This review will present a comparative analysis of ligand binding pockets in chemokine receptors, including a review of the CXCR4, CCR2, CCR5, CCR9, and US28 X-ray structures (section 2), and their implication for modeling interactions between chemokine receptors and small-molecules and larger peptide-like and chemokine ligands (sections 3−6). We will demonstrate how the combination of these chemokine receptor structures with extensive structure−activity relationship and site-directed mutagenesis data can be used to rationalize and predict structural determinants 49 ) of chemokine receptors for which crystal structure and/or site-directed mutagenesis information on small-molecule ligand binding is available (described in sections 2−5), including CCR1, 50, 51 75 Amino acid residues in CXCR4, CCR2, CCR5, CCR9, and US28 that are involved in receptor−ligand interactions are highlighted in bold and colored corresponding to the cocrystallized ligands 29 and 58 (in CCR2), 16 (CCR5), 30 (CCR9), 31, CVX15 and vMIP-II (CXCR4), and CX3CL1 and Nb7 (US28) according to the color coding in of chemokine receptor modulation (sections 3 and 4) and can facilitate the construction of structural models of chemokine receptor−ligand complexes that have not been crystallized yet (section 5). Finally, a review of virtual screening studies based on chemokine receptor crystal structures and homology models will be provided as a basis to discuss the possibilities and challenges of structure-based chemokine receptor ligand discovery (section 6).
ANALYSIS OF CHEMOKINE RECEPTOR CRYSTAL STRUCTURES
To allow systematic comparison of the residues at different positions in the TM helices of different GPCRs, receptor residue numbers are annotated throughout this review by their Uniprot numbers (for specific receptors) as well as their Ballesteros− Weinstein residue number and secondary structure motif (as superscript). 39, 40 According to the Ballesteros−Weinstein rhodopsin family (class A) GPCR 39 residue numbering schemes, the single most conserved residue in each TM helix is designated X.50. 40 For the ECL2 and ECL3, similar residue numbering schemes have been applied. ECL2 residues are labeled 45.X, and the reference residue C 45.50 is a conserved cysteine forming a disulfide bridge with C 3.25 in TM3. 41 ECL3 residues are labeled 67.X, and the reference residue C 67.50 is a conserved cysteine forming a disulfide bridge with a conserved cysteine residue in the N-terminus of most chemokine receptors (with the exception of CXCR6). To distinguish receptor residues from chemokine/ peptide ligand residues, receptor residues are annotated as singleletter amino acid codes, while peptide and chemokine ligand residues are annotated as three-letter amino acid codes with residue number as superscripts (e.g., Arg 1 , arginine at position 1 
and CVX15 (PDB 3OE0) in CXCR4 crystal structures. 11 The smallmolecule antagonist 31 (pink carbon atoms) binds the minor binding pocket (TMS1) of CXCR4, whereas the peptide antagonist CVX15 (cyan) mainly targets in the major binding pocket (TMS2). (b) Three-dimensional quantitative structure−activity relationship (3D-QSAR) model of 13 analogues of CXCR4 antagonist 31 78 constructed using FLAP 79, 80 based on an alignment to the cocrystallized pose of 31 in CXCR4, 11 indicating that a hydrophobic interaction field between the methyl groups of the imidazothiazole ring system (cyan surface) and the six-membered ring is an important determinant for binding the minor binding pocket of CXCR4. (c) Detailed analysis of the binding mode of 16 (magenta carbon atoms) targeting both the minor and the major binding pockets in the CCR5 crystal structure (PDB 4MBS). 12 (d) Ligand-based pharmacophore model of some of the most representative CCR5 small ligands 16, 81 20 (TAK-220), 82 and 21 (Aplaviroc), 83 including four pharmacophore features: two apolar/hydrophobic moieties (Hyd1, Hyd2), a hydrogen bond acceptor/cationic feature (Cat&Don), and an aromatic (Aro) feature. The residues corresponding to the 16 bound CCR5 crystal structure potentially interacting with the model are shown as gray sticks. (e) Comparative structural interaction fingerprint (IFP) analysis of the binding modes of 31 and CVX15 in CXCR4 and 16, 20, and 21 in CCR5, presented in panels a, c, and d. The structural receptor−ligand interaction patterns are described by IFP bit strings encoding different interaction types between the ligand and the different CXCR4/CCR5 amino acid residues. Two-dimensional representations of the chemical structures of the small-molecule ligands 16, 20, 21 , and 31 are provided in Figures 11, 12. in the 16-residue cyclic peptide ligand CVX15, His 6 in the chemokine ligand vMIP-II).
2.1. CXCR4, CCR2, CCR5, CCR9, and US28 Chemokine Receptor Crystal Structures. The endogenous chemokine ligand of the CXCR4 chemokine receptor is CXC chemokine ligand 12 (CXCL12), also known as stromal derived factor-1 (SDF-1). CXCR4:CXCL12 signaling axis plays a role in several inflammatory diseases and cancers. 42 CXCR4 was the first chemokine receptor reported to be a coreceptor for HIV-1. 43 The marketed drug 1 10 targets CXCR4 to mobilize hematopoietic stem cells in the treatment of patients with nonHodgkin lymphoma (NHL) and multiple myeloma (MM). Three crystal structures have been reported for CXCR4 fused to the T4 lysozyme (T4L) with different cocrystallized ligands ( Figure 1a) : 11, 13 the small ligand 31 (IT1t) (PDBs 3ODU, 3OE6, 3OE8, and 3OE9, Figures 1a, 3a) , the 16-residue cyclic peptide ligand CVX15 (PDB 3OE0, Figures 1a, 3a) , and the viral CC chemokine vMIP-II (PDB 4RWS, Figure 1b , 4a,c)). CCR2 binds CCL2, CCL7, CCL9, CCL11, CCL12, CCL13, CCL24, and CCL26 CC chemokines 1 and is implicated in inflammatory and neurodegenerative diseases. 44 Recently a crystal structure of T4 lysozyme fused CCR2 has been reported in a ternary complex with an orthosteric antagonist 58 (BMS-681) 45 and an allosteric antagonist 29 (CCR2-RA-[R]) 46 bound to an intracellular pocket (PDB 5T1A, Figures 1f, 5) . 15 CCR5 binds CCL2, CCL3, CCL4, CCL5, CCL8, CCL11, CCL13, and CCL14 CC chemokines and is the major HIV-1 coreceptor. 1 The FDA approved CCR5 antagonist 16 9 is used for the treatment of patients with HIV (R5-tropic HIV-1), and a crystal structure of rubredoxin fused CCR5 bound to 16 (PDB 4MBS, Figures 1d, 3b ) has been reported. 12 CCR9 activation by CCL25 plays a key role in leukocyte recruitment to the gut and is a therapeutic target in inflammatory bowel disease. 47 A CCR9 crystal structure has recently been solved, including seven thermostabilizing mutations, in complex with the selective allosteric CCR9 antagonist 30 (Vercirnon) bound to the same intracellular pocket as 29 in the CCR2 crystal structure (PDB 5LWE, Figures 1e, 5) . 16 US28 is a chemokine-like receptor encoded by the human cytomegalovirus that binds different chemokines such as CX3CL1, CCL5, CCL2, and CCL3, among others, in part as a strategy to evade the host immune system. 48 Two crystal structures have been reported for US28 bound to the human CX3CL1 chemokine, 14 Figure 4. Details of chemokine binding to CXCR4 (PDB 4RWS 13 ) and US28 (PDB 4XT1 14 ). (a) vMIP-II N-terminus binding to CXCR4 (pale yellow). 13 The N-terminus of vMIP-II (dark-green sticks) binds primarily in the minor pocket that is also targeted by 31 (transparent pink sticks), interacting with W94 2.60 , D97 2.63 , and E288 7.39 but also partially binds the major binding site, interacting with D262 6.58 .
(b) CX3CL1 N-terminus (light green sticks) binding to US28 (gray).
14 CX3CL1 N-terminus, as well as vMIP-II, binds mainly in the small binding site, interacting with Y40 1.39 , T175 45.52 , and E277 7.39 but also partially occupies the major binding site. CCR5 antagonist 16 is shown as transparent magenta sticks as reference. (c) vMIP-II (dark green) and CX3CL1 (green) superimposition. The overall architecture is conserved: the N-terminus inside the TM domain and the core to the extracellular surface (CRS1). (d) Comparative structural interaction fingerprint (IFP) analysis of the binding modes of vMIP in CXCR4, and CX3CL in US28, presented in panels a−c. The structural receptor−ligand interaction patterns are described by IFP bit strings encoding different interaction types between the ligand and the different CXCR4/US28 amino acid residues. Two-dimensional representations of the chemical structures of the small-molecule ligands 16 and 31 are presented in Figures 11, 12 one with the nanobody 7 (Nb7) (PDB 4XT1, Figure 1c ) bound to the intracellular surface of the receptor, and the other one without the nanobody (PDB 4XT3). US28 shares lower sequence similarity with CXCR4 (30%) and CCR5 (27%) than with the human CX3CR1 chemokine receptor (38%). The US28 crystal structure nevertheless shares a similar fold with CXCR4, CCR2, CCR5, and CCR9 structures, which allows comparison of the ligand binding modes and receptor conformations ( Figure 1−4) . Figure 2 shows a structure-based sequence alignment of chemokine receptors.
Comparison of Ligand Binding
Modes in Chemokine Receptor Crystal Structures. The 7TM ligand binding pockets of CXCR4, CCR5, US28, CCR2, and CCR9 chemokine receptor crystal structures are less buried and more solvent accessible than in the crystal structures of other crystallized class A GPCRs. 76, 77 The more open pocket of chemokine receptors is covered to a lesser extent by the extracellular loop 2 (ECL2) than in most other GPCR crystal structures (not solved in CCR9 crystal structure 16 ), which can be related to the fact that chemokine receptors bind chemokines that are larger than the natural ligands of other receptors. In addition, the binding pockets of chemokine receptors contain several negatively charged residues that are involved in ligand binding, as observed in crystal structures (Figures 1−5 ) and indicated by mutation studies (18) (19) (20) .
Small-molecule antagonists 31 and 58 exclusively bind the minor pockets (TMS1) of CXCR4 (Figures 1a, 2, 3a) and CCR2 (Figures 1f, 2, 5a) , respectively, located in the core of the TM domain, comprised by TM helices 1−3 and 7, whereas the small-molecule antagonist 16 binds both the minor and the major pocket (TMS2, including residues of TM 3−7) of CCR5 (Figures 1d, 2, 3b) . The N-termini of vMIP-II and CX3CL1 chemokines also bind both minor and major pockets of CXCR4 and US28, respectively (Figures 1, 2, 4) . The peptidomimetic ligand CVX15 primarily targets the major pocket, (Figures 1a, 2, 3a) . The globular cores of the chemokines interact with the extracellular surface of the receptors, including the top of the TM helices, the EC loops, and the receptor N-terminus (Figures 1, 3c, 8 ). Small-molecule allosteric antagonists 29 46 and 30 and the G-protein mimic Nb7 bind intracellular binding pockets ( Figure 5 ) of CCR2, CCR9, and US28, respectively.
2.2.1. Minor Pocket (TMS1). In the minor pocket, one of the positively charged nitrogens of the isothiourea group of 31 and the N-terminus amino group of vMIP-II form a salt bridge with CXCR4 D97
2.63 ( Figures 3−4) . The other crystallized chemokine receptor ligands that bind in the minor pocket, 16, 58, and CX3CL1, do not interact with the residue at position 2.63 (a serine in CCR2, and a tyrosine in CCR5 and in US28). The conserved W 2.60 residue is involved in interactions with all the ligands binding the minor pocket, including an edge-to-face aromatic interaction with one of the phenyl rings in the isothiourea group of 31 and an hydrophobic interaction with Leu 1 of vMIP-II for CXCR4, a face-to-face aromatic interaction with the triazole ring of antagonist 16 in CCR5, an hydrophobic packing with the trisubstituted cyclohexane of compound 58 ( Figure 5 ), and an edge-to-face aromatic interaction with His 1 of CX3CL1 in US28 (Figures 2−4) . Another conserved residue in the minor pocket, E 7.39 ( Figure 2 ), is involved in ionic and/or hydrogen-bond (H-bond) interactions with four of the five cocrystallized ligands that target TMS1, forming: (i) a salt bridge with the protonated nitrogen of the imidazothiazole feature of 31, (ii) an H-bond with Ala 3 backbone of vMIP-II in CXCR4, (iii) a salt bridge with the protonated nitrogen of the tropane group of 16 in CCR5, and (iv) a hydrogen bond with His 2 of Figure 5 . Figure 5 ). The 6-trifluoromethyl quinazoline moiety of 58 protrudes from the minor pocket of CCR2 toward the membrane bilayer, interacting with the membrane-oriented residues L44 1.34 and V289 7.37 ( Figure 5 ). 2.2.2. Major Pocket (TMS2). In the major pocket (TMS2), the negatively charged D 4.60 forms a salt bridge with Arg 2 of CVX15 in the CVX15 bound CXCR4 crystal structure (Figure 3a ).
11
The residue at position 4.60 is however not conserved among chemokine receptors (it corresponds to a glycine in CCR5 and to a histidine in US28, Figure 2 ) and it does not interact with other cocrystallized ligands. Figure 1− (Figure 3a ) and the benzene moiety of 16 (Figure 3c ), respectively, but are not interacting with the cocrystallized chemokines in CXCR4 or US28. The negatively charged D 6.58 that is conserved within CXC chemokine receptors ( Figure 2 ) forms a salt bridge with CVX15 (Arg 14 , Figure 3a ) and forms two hydrogen bonds with vMIP-II (His 6 and Arg 7 , Figure 4a ) in CXCR4 but is not involved in CX3CL1 chemokine binding to US28. An additional feature in the major pocket includes a hydrophobic subpocket located deep in the TM domain (defined by Y108 3.32 , F109  3.33 , F112  3.36 ,  W248 6.48 , and Y251 6.51 ) that is targeted by the phenyl group of 16 in CCR5 but not by other cocrystallized chemokine receptor ligands.
2.2.3. Extracellular Region. Crystal structure and sitedirected mutagenesis studies suggest that the extracellular surface of chemokine receptors is an important interaction site for chemokine and peptide ligands, including the cocrystallized chemokines vMIP-II (CXCR4) 13 and CX3CL1 (US28) 14 and the peptidomimetic CXCR4 ligand CVX15 11 ( Figures 1−4 ). Small ligands like the cocrystallized 31 (in CXCR4), 58 (in CCR2), and 16 (in CCR5) primarily interact with the minor and/or major pocket in the TM domain and make few interactions with, in particular, the extracellular loop 2 (Figures 1−3, 5) . 1, 2, 4 The positively charged Arg 1 residue of the peptidomimetic ligand CVX15 forms a salt bridge with the negatively charged D187 45.51 residue in ECL2 of CXCR4, while Arg 2 forms H-bond interactions with the backbone of R188 45.52 and Y190 45.54 ( Figure 1g ). The solved residues of the N-terminus of CXCR4 (S23 8.48 , R323 8.49 , and F324 8.50 ), pyridine-N-oxide (T81 2.37 and R323 8.49 ), and ketone moieties (T256 6.37 ). The intracellular pocket of US28 is occupied by the nanobody Nb7 (Figure 6b ), which is stabilizing the active-like conformation of the receptor (section 2.3). The 116 residues of Nb7 occupy a large volume in the intracellular part of the receptor, interacting with the intracellular half of all TMs, intracellular loops (ICLs), and with the C-terminus. The binding mode of Nb7 is similar to other reported nanobody-bound GPCR structures. 85, 86 The conserved R129 3.50 of the DRY motif in US28 ( Figure 2 ) interacts with Nb7 via van der Waals interactions and water-mediated H-bond interactions with the side chain and backbone of Ile, 101 respectively (Figure 6b The N-terminus of the receptor adopts slightly different conformations in every crystal structure, but in general these conformations are similar for the crystals binding nonchemokine ligands: the N-terminus is oriented toward the center of the TM domain, partially covering the access to the binding site. The N-terminal of CCR9 adopts an α helix conformation (F33 N-ter :C38 N-ter ) that orients toward ECL2. The N-terminal of CCR2 has not been solved. For the crystal structures binding chemokines, the N-terminus is almost perpendicular to the membrane due to the size of the chemokine, which is occupying the extracellular vestibule (ECL1, 2, 3, and N-terminus). ECL1 has the same conformation in CCR2, CCR5 and CXCR4, stabilized by a tryptophan residue (W 23.50 ) that is
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Perspective highly conserved among the chemokine receptor subfamily 90 and which is present in most class A GPCRs. The ECL1 of US28 does not contain this stabilizing W 23.50 residue and has not been solved in the US28 crystal structure, possibly reflecting a relatively higher flexibility of ECL1 in this receptor. ECL1 and ECL2 have not been solved in the CCR9 crystal structure. ECL2 contains a double beta strand, and it adopts a more open conformation in all the crystal structures than in nonpeptide binding GPCRs (e.g., rhodopsin 89 ). In ECL2, a disulfide bridge is highly conserved between the most conserved residue, C 45.50 , and C 3.25 in the top of TM3 (Figure 2) . A structural alignment between CCR2, CCR5, and CXCR4 crystal structures reveals that the loop connecting the beta hairpin of ECL2 of CXCR4 and CCR2 (A180 45 45.47 ), reflected by a 3−6 Å shift of the position of the C α atoms of D181 45.45 (CXCR4) and D185 45.45 (CCR2) compared to G173 45.45 (CCR5 45.45 in US28 and D181 45.45 in the 31 bound CXCR4 structure). Superimposed with the vMIP-II bound CXCR4 structure, CX3CL1 would clash with the ECL2 of CXCR4. The N-terminus region of TM7 of the chemokine receptor crystal structures is 1−2 helical turns longer than in most other class A GPCR crystal structures and is stabilized by a conserved disulfide bridge between C 67.50 at the top of TM7 and a cysteine in the N-terminus of the receptor. Comparison of the released chemokine receptor crystal structures (Figure 1) shows that ECL3 has a similar conformation in all structures. Within the TM domain of chemokine receptors, TM1 top is one turn longer in the vMIP-II bound CXCR4 structure and CX3CL1 bound US28 structure and it is laterally shifted outward (e.g., ∼6 Å between the Cα atoms of E32 N-ter in the 31 and vMIP-II bound CXCR4 structures). There is a unique helical kink in TM2, induced by the motif S/T 2.56 XP 2.58 , that places the residues 2.60 and 2.63 toward the ligand-binding site instead of to the membrane interface as in other GPCRs. 91 The top of TM3 in the CCR9 crystal structure is tilted inward the TM domain compared with the other structures (e.g., ∼7 Å between the Cα atoms of C119 3.25 in CCR9 and C109 3.25 in the 31 bound 
Perspective CXCR4 structure). In CCR5 and US28, the top of TM4 is more bent inward than in CXCR4 (reflected by a 3−4 Å shift of the C α atoms of N163 4.60 and H162 4.60 compared to D171 4.60 , respectively), resulting in a more closed binding pocket between TM3, TM4, and TM5 in CCR5 and US28 compared to CXCR4. In CCR9, the extracellular part of TM5 is bended outward the TM domain compared to the other structures (e.g., ∼8.5 Å between the Cα atoms of K209 5.33 in CCR9 and L210 5.33 in the 31 bound CXCR4 structure). The extracellular half of TM6 and TM7 adopt a slightly different conformation for all the crystal structures, but there are not significant differences due to the conserved disulfide bridge between TM7 and the N-terminus, with the exception of the top of TM6 in CCR9, laterally tilted and subtly bended inward the TM bundle (e.g., ∼5 Å between the Cα atoms of A281 6.62 in CCR9 and L266 6.62 in the 31 bound CXCR4 structure). residues. (ii) TM6 is shifted outward from the TM bundle (Figure 6a ), resulting in a shift of 5 Å between the C α atoms of G224 6.31 in US28 and R235 6.31 in the 31 bound CXCR4 structure, facilitating interactions with Nb7 or helix 8 (H8) in US28 structures. This shift is considerably bigger in crystallized full-active GPCRs, including beta-2 adrenergic receptor, 87 A 2A adenosine receptor, 88 and rhodopsin 89 (resulting in a distance of 8, 6.3, and 3.2 Å in between the respective C α of residue 6.31) as illustrated in Figure 6 . R 3.50 of the conserved DRY motif (Figure 2 ) stabilizes the inactive conformation of most class A GPCRs via an "ionic lock" 92 with an acidic residue at position 6.30 that is present in most class A GPCRs but not in chemokine receptors or US28 (K223 6.30 ). Nevertheless R129 3.50 is oriented inward toward the center on the TM domain in US28 (Figure 6a and 7a) in a similar way as in the active beta-2 adrenergic receptor structure (Figures 6b and 7b) , 86 A 2A adenosine receptor (Figures 6c and 7c) , 88 and rhodopsin (Figures 6d  and 7d) , 89 completing the hydrogen-bond network between TM helices 3 (R In addition to these conformational differences associated with the receptor activation state, there are several structural differences in the intracellular loops and H8 of CCR2, CCR5, CCR9, CXCR4, and US28 crystal structures that can be related to differences in protein constructs and/or crystallization. ICL1 has not been solved in CVX15 and vMIP-II bound CXCR4 structures, but a structural alignment of the other structures shows that the end of TM2 in CXCR4 is bent inward, reflected by a relative shift of 5 Å of the C α atoms of CXCR4 S71 ICL1 and US28 C66
ICL1 . ICL2 adopts an alpha helical conformation in CCR2, CCR5, and CCR9 that runs parallel to the membrane (A145 ICL2 −R152 ICL2 in CCR2, A133 ICL2 −R140 ICL2 in CCR5, and A151
ICL2 −E159 ICL2 in CCR9) and is not observed in CXCR4 (A141 ICL2 −S144 ICL2 ) and US28 (V134 ICL2 −P140 ICL2 ) structures. ICL3 has been replaced by lysozyme and rubredoxin fusion proteins in CXCR4 and CCR2 and CCR5, respectively, and has been solved for CCR9 and US28. In CCR2, CCR5, CCR9, and US28 structures, H8 has an α helix conformation that runs in parallel to the membrane as observed in most class A GPCRs crystal structures. In the nanobody-free US28 structure, H8 is oriented toward the intracellular binding site, stabilized by crystal packing. In CVX15 and vMIP-II bound CXCR4 structures, H8 has not been solved, but in the 31 bound CXCR4 structure, the unstructured C-terminus of H8 interacts with the TM pocket of the neighboring CXCR4 protein in the crystal lattice. while 606 mutation data points have been used to study the epitopes of nine different antibodies. 21, 68, 71, 72, 96, 106, 107 Sections 3.1 and 3.2 will provide crystal structure-based analyses of CXCR4, CCR2, CCR5, CCR9, and US28 mutation data, while section 5 will discuss how receptor mutation data can be used to model interactions between small-molecule ligands and chemokine receptors for which no crystal structure has been reported.
CRYSTAL STRUCTURE-BASED ANALYSIS
3.1. Structural Determinants of Chemokine Binding. Chemokines are soluble proteins of low molecular mass (7−12 kDa) and about 70−90 residues 77, 117 that share a conserved structural fold observed in the different chemokine crystal structures 118−120 (Figure 9a ). The conformation of chemokines is stabilized by two disulfide bonds: a N-terminus coil of variable length, followed by the cysteine motif (C, CC, CXC, or CX 3 C), linked through an N-loop to the globular core of the chemokine, consisting on a 3 10 helix turn, three antiparallel beta strands, and followed by an α helix on the C-terminus. The disulfide bonds connect the N-terminus of the chemokine to (1) the loop between the first and the second beta strand and (2) −Cys 12 in CX3CL1) interacts with the TM pocket, while the core of the chemokine interacts with the extracellular part of the receptor. This topology is also supported by a large amount of experimental data, including disulfide trapping experiments, dimer dilution experiments, bioluminescence resonance energy transfer (BRET), and coimmunoprecipitation, mutation studies, among others, 84, 111, 121 and is consistent with NMR structure of CXCL8 bound to the N-terminus (residues 9−29) of CXCR1 122 ( Figure 9b ). The experimentally supported topology does not seem to be compatible with the geometry of NMR models of CXCL12 bound to the N-terminus of CXCR4. 18 In these NMR structures the N-terminus peptide of CXCR4 (residues 1−38) is interacting with the chemokine in a way that is not compatible with the crystal structure topology. As shown in Figure 9b , the N-terminus peptide, including the C-terminal residue K38 1.32 , is oriented in parallel to the membrane, instead of pointing into the membrane (where TM1 is) as P17 N-ter of the CXCR1 model. The geometry of these models assumes that CXCR4 adopts a bent conformation, facilitating extensive interactions with the TM domain. 123 The accumulated pharmacological, biophysical, and structural biology data indicate that chemokines bind their receptors via a two-step process involving two different sites, 2,124 chemokine recognition sites 1 and 2 (CRS1, CRS2). This two-step binding model is consistent with the recently solved chemokine bound CXCR4 and US28 crystal structures, as described in sections 3.1.1 and 3.1.2.
3.1.1. Chemokine Recognition Site 1 (CRS1). First the globular core of the chemokine (including the N-loop) binds to the N-terminus, the extracellular loops, and some residues on the top of the TM domain of the receptor (step 1), which is called chemokine recognition site 1 (CRS1). Mutations in CRS1 are shown to reduce the affinity of the chemokine (Figure 8, 10 95 Mutations of the chemokine 
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Perspective core also reduce the affinity of the chemokines for their receptors ( Figure 9d ): for CXCL8, those positions that, when mutated, significantly reduce the affinity for the receptor, are also the positions that interact with the receptor N-terminus according to the NMR model, including Phe 17 , Phe 21 , Leu 43 , and Leu 49, 127, 128 The same occurs with the CX3CL1 bound CX3CR1, 129, 130 where mutations of Lys 14 , Lys 18 , and Phe 49 , for example, reduce the affinity of the chemokine for the receptor more than 10-fold. This first interaction site has been reported to be the mainly responsible for receptor affinity, while it is less involved in receptor activation and function.
111 

Perspective
Sulfation of Y21 N-ter in the N-terminal region of CXCR4 increases the binding affinity for CXCL12, 18 and homologous sulfated tyrosine residues are suggested to play a similar important role in the recognition of chemokine ligands by other chemokine receptors. 131 Sulfation of tyrosine residues in the CXCR4 N-terminal has been shown to be relevant in CXCR4-mediated metastasis. 132 A sulfate ion observed in CXCL12 crystal structures (PDBs 1A15, 1QG7, 4UAI) has been proposed to mimick the sulfated sY21 N-ter residue. 133, 134 136 A predicted interaction interface between the CXCR4 N-terminus and CXCL12 has been used to identify low affinity binders of CXCL12 in virtual screening studies. 50 values of wild-type and mutant <−0.5 (cyan), −0.5 to 0.5 (blue), 0.5 to 1.0 (yellow), and >1.0 (red) log units for chemokines are reported and color coded (annotated data set included in Supporting Information). 18, 111, 121, 134, 135 The secondary structure motifs are indicated in boxes. Residues of vMIP-II and CX3CL1 interacting with the receptors CXCR4 and US28 respectively in the corresponding crystal structures are highlighted in bold gold. The aligned cysteines involved in the disulfide bridges that stabilize the chemokine tertiary structure are surrounded by a blue box. The first CXCL8 residues in a gray background correspond to an alternative but minority isoform also active in physiological conditions.
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Perspective the chemokine interacts with the core of the TM domain (minor pocket TMS1 and partially the major pocket TMS2) and ECL2. 2 In the CXCR4:vMIP-II crystal structure, the main interactions within the 7TM binding pocket and the chemokine include hydrogen bonds with residues D97 for CXCL12 binding affinity and/or potency for CXCR4 ( Figure 10 ). 21,68,69,105,106,111−113 Mutation studies furthermore suggest that also the anionic D171 4.60 (which does not interact with vMIP-II in the CXCR4 crystal structure) and D187 45.51 (mutated to a cysteine residue for a covalent attachment with Cys 5 in vMIP-II) residues are also important anionic residues for CXCL12 affinity and/or potency for CXCR4 73, 74, 78, 84, 105, 111 ( Figure 10 ). Consistent with the vMIP-III bound CXCR4 crystal structure, mutation studies show that W94 2.60 plays an important role in binding CXCL12 in the minor pocket of CXCR4, 69, 74 whereas mutation of Y116 3.32 at the interface between the minor and major pockets does not affect CXCL12 affinity (Figure 10c ). 69 The main interactions in the TM domain of the CX3CL1 bound US28 structure are hydrogen bonds with Y40 115 Comparative analysis of chemokine receptor mutation data show however that the role of residue positions 1.39, 2.63, 3.32, 6.48, 6.51, 6.55, 7.39, and 7.43 are highly chemokine−receptor complex dependent ( Figure 8 ). Mutation of Y 1.39 in the minor pocket does not affect the affinity of CXCR4 for CXCL12 69 ( Figure 10c ) or the affinity of CXCR3 for CXCL11 63 ( Figure 19f ) but does affect CCR2 binding affinity for CCL2 53 nor CCR5 affinity for CCL3. 54 Mutation of Y89 2.63 in the minor pocket of CCR5 decreases the potency of CCL4 and CCL8 but does not affect the potency of CCL3 and CCL5, 55, 90, 99 whereas mutation of D112 2.63 affects binding of CXCL11 to CXCR3 63, 64 and mutation of S103 2.63 decreases the binding combinations covering 42 residues (annotated mutation data set included in Supporting Information). 68, 69, 105, 106, 108, 111, 112 Maximum mutation effects are mapped on: (a) CXCL12 (green) bound CXCR4 structure (modeled based on the vMIP-II bound CXCR4 crystal structure (PDB 4RWS), 13 and (b) CXCR4 snakeplot adapted from GPCRdb. 143 Residues involved in ligand interactions for the vMIP bound CXCR4 crystal structure are encircled in green. Effects on CXCL12 affinity and potency are annotated by background and amino acid color, respectively. Mutation data derived from antibodies inhibition binding is not shown. (c) Summary of CXCR4 site-directed mutagenesis effects on CXCL12 binding/potency in individual studies. A recent study has been published reporting single-point binding and functional data of all CXCR4 residues mutants, which has indicated that in particular W94 2.60 and D97 2.63 are critical for CXCL12-mediated signaling. 74 
Perspective affinity of CXCL11 and CXCL12 for ACKR3. 115 Mutation of the residue at position 3.32 at the interface between the minor and major pockets affects binding affinity of CCL2 for CCR2, 52, 53, 94 CCL5 for CCR5, 90 and potency of CCL1 for CCR8. 59 Substitution of residue 3.32 however does not affect the binding affinity of CXCL8 for CXCR1 125 or CXCL11 affinity for CXCR3. 63, 67 Mutation of the residue at position 7.39 negatively affects binding affinity and/or potency of CXCL11 for CXCR3 (S304 7.39 ), 65 CXCL11 for ACKR3 (Q301 7.39 ), 115 CCL2 for CCR2, 53 ,94 CCL3 for CCR5, 58 and CCL5 for CCR5, 55 whereas Figure 11 . (a) Chemical structures of CXCR4 ligands investigated in CXCR4 mutation studies. 21,68−73 Interactions between the ligands and specific residues derived from CXCR4 X-ray structures (bold), mutation studies (gray), or models without support from experimental data (gray italics) are depicted by dotted lines. 
Perspective mutation of E 7.39 does not affect binding affinity/potency of CXCL8 for CXCR1, 125, 126 CXCL8 for CXCR2, 60,61 CXCL12 for ACKR3, 115 or CCL1 for CCR8. 59 The effects of single point mutations in the major binding pocket on chemokine ligand binding are receptor dependent (Figure 8 62 Mutation studies indicate that residues in the N-terminus of chemokines are important for both binding affinity and receptor activation ( Figure 9d ) and that most residues in the CRS2 of chemokine receptors play a more important role in chemokine mediated receptor activation than in chemokine binding. 111 The binding of small ligands occurs also in CRS2 (minor and major pocket of the 7TM helical domain) and will be described in more detail in the next sections. Recently, a human singledomain antibody-like scaffold (i-body) with antagonistic activity for CXCR4 (to nanomolar) has been reported 138 that is proposed to target a similar binding site as chemokines (PDB 5AEA, Figure 9c ). Epitope mapping revealed that i-bodies bind the transmembrane binding pocket of CXCR4 (including residues V112 3.28 , F189 45.53 , D262 6.58 ), whereas CXCR4 antibodies 139 and nanobodies 140 have been reported to target the extracellular loops (E179 45.43 , D181 45.45 ) and the N-terminus (C28 N-ter ) of the receptor. The best hits of engineered i-bodies all possess conserved positively charged Arg residues, complementary to the negatively charged binding pocket of CXCR4.
3.2. Structural Determinants of Small Ligand Binding to CCR2, CCR5, CCR9, CXCR4, and US28. CXCR4, CCR5, US28, CCR2, and CCR9 crystal structures ( Figure 1 ) and chemokine receptor mutagenesis studies (Figures 10−13 and 17−20) indicate that small-molecule ligands can bind chemokine receptors in the extracellular part of the TM domain, the minor pocket between TM1, TM2, TM3, and TM7, the major pocket between TM3, TM4, TM5, TM6, and TM7, and in the intracellular part of the receptor.
3.2.1. Minor Pocket in TM Domain (TMS1). Within the minor pocket (TMS1), the most important features are (i) Ionic interactions between D 2.63 and the cationic isothiourea group of the small ligand 31 at the top of the minor binding pocket are observed in the CXCR4 crystal structures (Figure 3a) . Mutation studies indicate that D 2.63 is important for the binding of ligands 15 (KRH-1636) 21 and 13 69 to CXCR4 (Figure 11 ) 21, 69 and also play a role in small-molecule ligand binding to CXCR3 (section 5.5). 63 It should be noted however that D 2.63 is not conserved within the chemokine receptor subfamily.
(ii) A polar interaction between T292
7.40 and the γ-lactam secondary exocyclic amine of the small ligand 58 at the interface of the minor pocket and the membrane bilayer. The role of T292 7.40 in CCR2 ligand binding is supported by T292 7.40 A/V mutation studies, resulting in a significant decrease in the affinity of 19 (TAK-779), 19-1 (TAK-779 base), 25, 26 (RS-504393), and 27 (Teijin) for CCR2 ( Figure 13) . 52, 53, 93 (iii) A hydrophobic subpocket in the lower region of the minor pockets of CXCR4, CCR5, and CCR2 contains conserved hydrophobic and aromatic residues, including Y Figure 12 ) according to mutant studies, validating the observed interaction with antagonist 16 in the CCR5 crystal structure. Y49 1.39 in CCR2 is involved in a hydrogen bond with the carbonyl oxygen of the γ-lactam of 58, and it has been confirmed to decrease the affinity of 19 in site-directed mutagenesis studies. 52 , which is present in most chemokine receptors (Figure 2 ). Mutation studies show that this residue is important for small-molecule ligand binding to CXCR4 (Figure 11) , 68, 144 CCR5 (Figure 12 ), 54−57 CCR2 (Figure 13 ), 52 and US28 (Figure 14) , 145 (Figure 11 ), suggesting that this residue plays a role in binding small-molecule ligands as well. (a) Chemical structures of CCR5 ligands with related mutation data. 54−58 Interactions between the ligands and specific residues derived from CCR5 X-ray structures (bold), mutation studies (gray), or models without support from experimental data (gray italics) are depicted by dotted lines. 
Perspective The residue at position 45.51 is however not conserved among chemokine receptors ( Figure 2 ) and mutation of this residue seems to be receptor and ligand dependent. in CXCR4 leads to a decrease in affinity for almost all the small ligands with which it has been tested ( Figure 11 ): (Figure 2 ), neither in physicochemical properties, meaning that this position cannot be involved in polar interactions in all the receptors. Thus, for CCR5 (glycine), most of the tested small ligands are not affected by 4.60 mutation to alanine (G163 4.60 A) ( Figure 12) ; only in the case in which this residue has been mutated to arginine (G163 4.60 R) it decreases the affinity of 21−23 57 ( Figure 12 ). Additionally, D/G 4.60 is not interacting with any of the two chemokines in vMIP-II bound CXCR4 and CX3CL1 bound US28 crystal structures. CXCL12 affinity and potency are decreased by the D171 4.60 N mutant in CXCR4, while the homologous D186 4.60 N mutation in CXCR3 does not affect affinity for CXCL11.
63,67 D 6.58 is conserved among CXCRs, while position 6.58 corresponds to a less conserved residue in CCRs (Figure 2 ). Mutation studies show that this residue plays an important role in binding small-molecule ligands to CXCR4 (Figure 11 ). 21,68−72 (ii) A hydrophobic subpocket located in the major pocket of CXCR4 (Y116 ), CCR5 179 Interactions between the ligands and specific residues derived from X-ray structures (bold), mutation studies (gray), or models without support from experimental data (gray italics) are depicted by a dotted line, interacting groups are surrounded by a dotted line, and key features are summarized by a solid box. Mutation data for the US28 ligand 45 145 is also included in a squared box. For each ligand, the binding affinity (IC 50 90 ) is reported (except for compound 35, for which functional IC 50 is reported, and for compound 60 K i is based on MOLT-4 cells).
Perspective ( Figure 11) . 68, 69, 71 Mutation of I198 5.42 , which interacts with the cyclohexyl group of 16 in the CCR5 in the same hydrophobic binding site (Figure 3b ), results in a 3−125-fold decrease in affinity and/or potency of all small ligands evaluated in CCR5 studies (16, 57, 55 . As described in section 2.2.4, 29 and 30 bind the intracellular pocket. This was predicted before for 29 by mutagenesis data that confirmed the relevance of residues 7.53 and 8.50 for binding affinity of this compound to CCR2, 93 and it has been validated for 30 also through sitedirected mutagenesis assays. 16 (iii) Polar interaction with ICLs and H8. S220 ICL3 of US28 forms an H-bond interaction with Glu 99 in Nb7. The polar Glu 104 side chain of Nb7 is located between the end of TM6-ICL3 and the end of TM7-H8 and makes a polar interaction with H222 ICL3 and T296 8.48 (Figure 7a ,e). These residues also make polar interactions with the Gs and miniGs in beta 2AR and A2A, respectively (Figure 7e) The chemokine receptor crystal structures with different cocrystallized ligands constitute a valuable source for retrospective ligand search through structure−activity relationship studies, and they provide an important clue to the binding mode prediction for derivatives and other ligand chemotypes. 77 The current section is dedicated to the compilation and analysis of the different strategies and results regarding binding mode prediction and its mutual contribution to drug design. 4.1. CXCR4−Ligand Structure−Activity Relationships. For CXCR4, 949 mutation data points have been determined covering 96 different residues positions, 20 chemokines/ antibodies, and 18 different small ligands (including 1−15, Figure 11 ). D171 A and H281 7.32 A mutation affected potency of 2, 3, and 4.
68 All together, the mutation data suggest that ligands 3−11 and 14 primarily target the major pocket, while ligands 1, 2, 13, and 15 target the minor and the major pocket simultaneously (Figure 11 ). CXCR4 binding affinity of 14 (KRH-3955) is not affected by mutation of D171 4.60 , D262 6.58 , and E288 7.39 but may be dependent on interactions with other negatively charged residues in CXCR4, such as D97 2.63 and D181 45.45 , as proposed in CXCR4 modeling studies. 73 SAR studies provide insights into the determinants of binding affinity of 31 analogues to CXCR4
78 that are consistent with the 31 bound CXCR4 crystal structure (Figure 3e ), 11 showing that (i) the two protonated nitrogen moieties interacting with D97 2.63 and E288 7.39 are essential for ligand binding affinity, (ii) two aliphatic six-, seven-, or eight-membered rings are essential for optimal binding of the hydrophobic subpocket between W90
2.60 , H113 3.29 , and Y116 3.32 ( Figure 14) . The 3D-QSAR model presented in Figure 3b , derived from FLAP based on an alignment of analogues of 31 to the crystallized conformation of 31, 78 shows that a tight fit of apolar moieties in the hydrophobic subpocket between W94
2.60 and Y116 3.32 is required for high affinity binding, consistent with other druggability assessments of the minor CXCR4 binding site. 76 Combined SAR, 151, 152 mutagenesis, and modeling studies 21 suggest a binding mode in which the guanidine and the amine group of antagonist 15 interact with D171
4.60 and D262 6.58 residues, respectively ( Figure 11) , consistent with SAR studies showing that the guanidine moiety, the position of the nitrogen atom in the pyridine, and the S-stereo configuration of 15 are important for CXCR4 binding. The cyclam and pyridine moieties of 1 and its derivatives 2, 5, and 6 (Figure 11a ) play important roles in CXCR4 binding affinity and are proposed to interact with Y45 21 SAR studies indicated that the basicity of the benzoimidazole, the length of the aliphatic amine group, and the S stereoconfiguration are important requirements for 13 binding affinity. Different putative binding modes of 13 in relation to SAR and mutagenesis data will be discussed in more
Perspective detail in section 5.3 ( Figure 17) . 69, 153 The replacement of any of the two basic amines with amides and the modification of the pyridine rings into phenyl, methyl, or guanidine groups significantly reduce the potency of antagonist 32, indicating that these cationic and/or aromatic groups are important for 32 binding and/or CXCR4 activation. 154 The central phenyl ring and linker length between the aromatic ring and the terminal hexenamine moiety are important determinants of the binding affinity of compounds 33 and 34 for CXCR4. 155, 156 On the basis of this SAR data, binding modes have been proposed for 33 and 34 in which the cationic piperazine/piperidine interact E288 7.39 and D193 45.57 , respectively. The combination of CXCR4 mutation data and SAR studies suggest that the essential aromatic quinazoline of 33, purine of 34, Figure 12 ). E283
7.39 A mutation resulted in a significant decrease of binding of ligands 16−23, suggesting a binding mode in which the negatively ionizable E283
7.39 residue is involved in an ionic interaction with the positively charged basic nitrogen atoms of these ligands (Figure 12a) indicating that these ligands are in a similar way targeting the minor and major pocket simultaneously (Figure 3d ). On the basis of this structure-based alignment a pharmacophore model for CCR5 ligands can be defined consisting of: (i) one basic feature (the basic amine of 16 that interacts with E283 163 although this does not necessarily mean that all these ligands adopt a similar binding mode. Moreover, the symmetric distribution of hydrophobic/aromatic features compared to the central cationic feature offer a challenge to predicting CCR5−ligand binding modes in a similar way as CXCR4, as discussed in section 5.3. Despite these caveats, the structure-based CCR5 pharmacophore model facilitates a structure-based analysis of CCR5 mutagenesis ( Figure 12 ) and SAR (Figure 14) (Figure 3d ). The seven-membered ring of 19 167, 168 is preferred over the six-membered ring, while the optimal linker between the phenyl and quaternary ammonium groups is one carbon atom, suggesting that the relative distance and directionality of the cationic and aromatic/hydrophobic groups are essential for CCR5 binding. The hydrophobic substituents of the benzene ring of 20 82 are favorable for CCR5 affinity, emphasizing the importance of this hydrophobic feature in the CCR5 ligand pharmacophore (Figure 14) .
The modification of the carbon linker between piperidine and benzene of 20 into a nitrogen atom results in a decreased affinity, 82 which may suggest that the conformational flexibility of the aromatic benzene ring to target the minor pocket is an important determinant of CCR5 affinity. The six-membered aliphatic ring and triazole groups of 16 can be replaced by aromatic 169 
174
) with the minor and/or major hydrophobic binding pocket of CCR2. SAR studies indicate that the stereochemistry of trisubstituted cyclohexane of 57 is important for CCR2 affinity, 45 in line with the tight packing of the corresponding cyclohexane ring of 58 against W98 2.60 in the CCR2 crystal structure ( Figure 5 ). The binding mode of 29 in the intracellular binding pocket observed in the CCR2 crystal structure 15 is consistent with earlier mutation studies showing the negative effects of V244 6.36 A, Y305 7.53 A, K311 8.49 A, and F312 A, D15 N-ter A, and Y16 N-ter A in the N-terminus region and E277 7.39 A in TM7) for four chemokines (CCL3, CCL4, CCL5, and CX3CL1) and one small ligand (45 (VUF2274)) ( Figure 14) . The F14 N-ter A mutant significantly decreased binding affinity of CCL3, CCL4, and CCL5 but not forms an ionic interaction with the piperidine amine of the ligand. 20 45 derivatives are the first reported nonpeptidergic inverse agonists of US28, and SAR studies indicate that the hydroxyl, chloro, and chlorobenzene features are essential for affinity, while the cyano group and the two phenyls are not necessary to maintain the affinity (Figure 14) . 180 Other small US28 ligands, 46 (methiothepin), 47 (octoclothepin) (Figure 14) , 181 and series of dihydroisoquinolinone, 48 (tetrahydroisoquinoline) 182 and 49 (flavonoid) 181 containing US28 agonists have similar low potency, 183 hampering SAR analysis. There are furthermore several US28 small ligand reported in patents, including 50 (arylamine), 184 51 (S(−)-IBZM), 185 and 52 (VUF6045), 186 but clear, quantitative SAR data is missing for these series.
EXPERIMENTALLY INFORMED MODELING OF CHEMOKINE RECEPTOR−LIGAND STRUCTURE
The community-wide GPCR DOCK 2010 assessment 20 to predict the three-dimensional coordinates of the 31 and CVX15 bound CXCR4 structures before release of the crystal structures, highlighted some of the challenges of predicting ligand binding modes in chemokine receptors. None of the GPCR DOCK 2010 participants were able to predict the binding pose of the large peptide CVX15 in the major pocket of CXCR4, demonstrating that the prediction of GPCR−peptide interactions is particularly difficult, especially in the absence of experimental modeling constraints. The key interactions of the small-molecule ligand 31 with D97
2.63 and E288 7.39 in the minor pocket of CXCR4 190 could only be correctly predicted by the explicit incorporation of CXCR4 mutation studies 69, 90 and ligand structure−activity relationship (SAR) 78 to guide the modeling of CXCR4 structure and CXCR4−ligand interactions. The GPCR DOCK 2010 challenge and other modeling studies have demonstrated that compared to other GPCRs families, chemokine receptor structures have a couple of peculiarities that require careful considerations. These include the positioning of the helix bundle, the extracellular domain, and the ligand binding sites, which pose different challenges for model construction. Furthermore, it should be noted that small-molecules ligand of different chemokine receptors are chemically diverse (Figures 11, 12 , 13, and 18−20) and that the effects of mutation studies are highly ligand dependent, limiting the possibilities to translate binding mode hypotheses between chemokine receptors and/or ligand chemotypes. While sections 3 and 4 provide a retrospective analysis of protein mutation and ligand SAR data of crystallized CXCR4, CCR5, and US28 receptors, the following sections 5 and 6 provide an overview of the implications of the new crystal structures on the construction of chemokine receptor models for the elucidation of the structural determinants of chemokine− ligand interactions (described in section 5) and the structurebased discovery and design of new chemokine receptor modulators (section 6). In the current section, the use of experimental anchors to steer the modeling procedure and address challenges associated with different steps along the modeling workflow ( Figure 15 ) will be discussed, including (step 1) amino acid sequence alignment, (step 2) template selection, (step 3) TM bundle and loop modeling, (step 4) ligand binding pocket prediction, and (step 5) ligand binding mode prediction. Although the workflow is sequential, the sequence alignment, template selection, and model building steps are interconnected and will be therefore described together in section 5.2. Different sequence alignment approaches will be described, based on GPCRdb structure-based sequence alignments, 49 manually curated based on the analyses of structural alignments. After building the initial model, more detailed information can be used to refine the binding pocket and the ligand binding mode, which will be discussed in section 5.3. We will provide an overview how protein site-directed mutagenesis studies (section 3) and ligand structure−activity relationships (section 4) have been used to map ligand binding sites, resulting in proposed binding mode models for numerous ligands in different chemokine receptors (CXCR2, section 5.4; CXCR3, section 5.5; CCR1, section 5.6; CCR2, section 5.7; and CCR8, section 5.8). It should be noted that the modeling requirements and challenges dependent on the purpose of the chemokine receptor model. Some models have been constructed with the purpose to closely capture receptor−ligand interactions or are optimized for structurebased virtual screening but nevertheless contain inaccuracies in specific regions in the TM domain. Other models provide an accurate structural architecture of the receptor−chemokine complex but do not offer insights into interactions on residue or atomic level. A schematic overview of the applicability domain of different chemokine receptor models is provided in Figure 15 .
5.1. Sequence Alignment and Template Selection for Chemokine Receptor Modeling. The prediction and modeling of the 31 and CVX15 bound CXCR4 crystal structures in the GPCR Dock 2010 20 was especially challenging because its similarity in both sequence and function compared to the GPCRs structures available at that time was distant (ADRβ 1 , 26% identity). A multiple sequence alignment of the target sequence with potential homologues is an important step toward the prediction of the structure of the target (step 1, Figure 15 ). Sequence motifs containing glycines, prolines, serines, and threonines are of particular interest because they are known to be involved in helix kinks/bulges. 191 An important challenge in the GPCR DOCK 2010 modeling assessment was the prediction of alternative conformation of the top of TM2, stabilized by the T 2.56 xP 2.58 motif that is conserved in chemokine receptors (section 2.3.1, Figure 2 and Figure 15) 1,20 and introduces a oneresidue gap resulting in a 100°rotation of the top of TM2 compared to the closest crystal structure template at that time ADRβ 1 . 23 The T 2.56 xP 2.58 induced helical bulge was correctly predicted by a molecular dynamics (MD) simulation based conformational analysis of TM2 and the consideration of mutation studies indicating that residues 2.60 and 2.63 (W94 2.60 and D97 2.63 in CXCR4) play a role in ligand binding to CXCR4 and other chemokine receptors and should therefore be oriented inside of the TM bundle ( Figure 15) . 20, 23, 69, 191 A structure-based alignment of the CXCR4, CCR2, CCR5, CCR9, and US28 crystal structures now facilitates the sequence alignment of the TM helices, as well as ECL1, ECL3, and large parts of ECL2. Alignment of the N-terminus, ECL2 (in particular upstream of the conserved C 45.50 ), ICL3, and C-terminal still remains challenging because of the variation of loop length and limited availability of structural templates for these regions (steps 1 and 2, Figure 15 ).
The overall conserved structural fold of the TM helical bundle of chemokine receptor crystal structures implies that the CCR5, CXCR4, CCR2, CCR9, and US28 structures represent useful templates for modeling the 7TM domains of other chemokine receptors. CCR5 shares sufficiently high sequence identity (≥40%) and similarity (≥60%) 20 to model the TM helices of
Journal of Medicinal Chemistry
Perspective CCR1, CCR3, CCR4, CCR8, ACKR2, and CCRL2, whereas CXCR4 shares sufficiently high sequence identity and similarity with CXCR1, CXCR2, and CXCR3, CCR2 shares sufficiently high sequence identity and similarity with CCR1, CCR3, CCR4, CCR7, CCR8, CCRL2, and ACKR2, CCR9 shares sufficiently high sequence identity and similarity with CCR1, CCR4, CCR6, CCR7, CXCR1, CXCR2, CXCR6, and ACKR4, while US28 provides a template for modeling the homologous CX3CR1 (Figure 16c ). Homology models or new crystal structures of CCR4, CXCR1, or CXCR2, and CXCR3 would provide homologous templates for chemokine receptors with lower sequence identity (<40%) or similarity (<60%) to the currently crystallized chemokine receptors. A crystal structure of CCR4 would be a homologous template to model XCR1, while CXCR1 or CXCR2 structures would provide a homologous template to construct models of CCR6 and CCR7, and an experimentally determined structure of CXCR3 would facilitate CXCR5 modeling. CCR10, CXCR6, ACKR1, and ACKR3/CXCR7 do not have high TM sequence identity/similarity with the three crystallized receptors or the 13 receptors for which high resolution homology models can be directly derived from chemokine receptor crystal structures. Binding site similarities show more distinct chemokine receptor clusters (Figure 16 ), and several receptors share significantly higher binding site similarity than TM helix similarity. For example, CCR5 provides a good template to accurately model the bindings site of CX3CR1 (62% identity), while it shares relatively high sequence similarity with ACKR3/CXCR7 (65% similarity) and US28 provides a good template to model the binding site of CCR8 (62% similarity). Variability of the length and sequence identity of the extracellular and intracellular regions, which conformations have been discussed in sections 2.3.1 and 2.3.2, may also influence template selection The implications of this variability for extracellular regions on prediction of interactions with chemokines will be described in section 5.2, and for interactions with intracellular effectors such as nanobodies, G-proteins, or beta-arrestin will be described in section 5.3. In addition to sequence similarity in the TM helices and putative binding pockets, several other criteria can be considered to select the appropriate (or combination of) homology modeling templates (step 2−3), including: (i) sequence motifs that determine the helical conformation, (ii) local sequence similarity in specific ligand binding sites, (iii) chemical similarity between the crystallized and modeled ligand, (iv) conformational Figure 15 . General GPCR molecular modeling workflow with specific details in chemokine receptor modeling customization and applications. For each step, specific details from experimental and in silico data concerning the target to model may be used to improve the approach. The left panel shows specific details on chemokine receptors modeling, including considerations in length, conserved residues (represented in orange), or conserved motifs (represented in pink) that can influence the orientation of specific residues in or out of the binding site (colored in green). The right panel summarizes the applicability domains of the structural models generated along the modeling workflow, ranging from the design of SAR and mutation studies and the generation of ligand repurposing hypotheses based on crystal structure-based sequence alignments, the identification of ligand binding sites, elucidation of ligand binding modes, and the application of structural models for structure-based virtual screening, structure-based ligand design, and the elucidation of ligand-mediated receptor activation mechanisms.
Perspective state (active/inactive), and (v) crystallographic artifacts. In addition to the conserved T 2.56 XP 2.58 motif that determines the fold of TM2, there are other sequence motifs that determine the conformation of helices in chemokine receptors, including the P 1.36 P 1.37 motif present in CCR5 and conserved also in CCR1, CCR2, CCR3, CCR4, and CCR9. This motif induces a different kink in TM1 than the alternative P 1.36 X 1.37 motif that CXCR4 shares with CCR6, CCR7, and CCR10. CXCR4 may therefore be a better template to model the conformation of TM1 of the latter three CC chemokine receptors. CXCR2 has a lower overall sequence identity with CCR5 (37%) than with CXCR4 (40%) but share residues F 3.36 , N 6.52 , and L 6.55 that are reported to be important for binding compounds 61 and 64 based on mutagenesis studies. 61 CCR5 may therefore be a better template to model 61 and 64 bound CXCR2. A chemical similarity analysis of known chemokine receptor ligands and cocrystallized class A GPCR ligands allows the identification of the most relevant template for ligand-bound chemokine receptor models. For example, the predicted binding orientation of 19 in the CCR5 crystal structure can be used to model the binding mode of 19 in the homologous CCR2 (70% binding site similarity, Figure 16 ), whereas a refined binding pose of 19 in the CXCR4 crystal structure would be a more suitable template to predict the ligand binding mode in the more homologous CXCR3. a) . Pairwise sequence similarity (lower-left) and identity (upper right) percentages are reported based on sequence alignment of (b) TM helices and (d) binding sites and are gradually color-coded from red to green. Cells surrounded by black squares correspond to data described in the text. Chemokine receptor binding site based clustering (c) has been performed based on the UPGMA algorithm with 100 replicas of bootstrapping (calculated using GPCRdb 49 ).
Perspective Derivatives of 19 have also been proven to bind CCR5 and CCR2. CCR5 would provide an accurate template to construct a 19 bound CCR2 homology model. 22 As pointed out before by others, 23 the 31 bound CXCR4 crystal structure (PDB 3ODU) contains two protruding lipids in the major pocket between TM5 and TM6, which constitute a crystallization artifact that conditions the orientation of these two helices. For ligand-bound models in which important interactions are characterized in the major pocket, the CVX15-bound structure may constitute a better template. The location of the receptor C-terminal into the TM bundle of the symmetry neighbor receptor in the crystal lattice may explain the presence of the lipids and the opened conformation of this structure (section 5.3).
Modeling Structural Interactions between Chemokine Receptor and Chemokine Ligands.
Comparison of the vMIP-II bound CXCR4 and CX3CL1 bound US28 crystal structures (section 3.1), the CXCL8, CXCL12, CX3CL1, and vMIP-II chemokine crystal structures and NMR models (section 3.1), chemokine/chemokine receptor mutation data (section 3), and chemokine/chemokine receptor sequences (Figures 1d and 4d) , indicate that the chemokine bound CXCR4 and US28 structures provide useful templates but also highlight potential challenges in the modeling of structural chemokine− receptor interactions. These challenges include first of all modeling of interactions between the chemokine C-terminal core region with the first 23 and 15 residues of each receptor N-terminus (missing in the CXCR4 and US28 structures, respectively) and the extracellular loops (in particular ECL2 that is differently positioned in the CXCR4 and US28 structures). To address this fact, the overall geometry of the chemokine bound chemokine receptor structure has to be defined a priori. The chemokine bound CXCR4 and US28 crystal structures provide evidence that supports the two-sites binding model in which the N-terminus of the chemokine interacts with the minor and major pockets in the 7TM helical bundle, while the chemokine core interacts with the receptor N-terminus and ECLs. 111 NMR models supporting alternative binding modes have been reported (Figure 9b ), suggesting that chemokines may adopt different binding orientations in complex with chemokine receptors. 18 The different binding modes of the N-terminus regions of the vMIP-II and CX3CL1 with the TM domain of CXCR4 and US28 indicate that both the structure and receptor interactions of the chemokine N-terminus will differ between chemokine bound receptor complexes. The N-terminus of chemokine receptors is highly variable in length and composition, and it has not been fully solved (step 3, Figure 15 ). For instance, CCR2 N-terminus is 12 residues longer than CCR5 N-terminus, while the CXCR2 N-terminus is 10 residues longer than the N-terminus of CXCR4. Modeling of a large part of the receptor N-terminus has to be done de novo, which is complicated because of the lack of knowledge of interactions between the chemokine and the N-terminus of the receptor and requires structural refinement by, e.g., MD simulations (step 4, Figure 15 ). For the modeling de novo of the N-terminus, there is a potential restraint to be used: the sulfotyrosine in position 21 in CXCR4 which has been predicted to bind in the disaccharide binding site, as explained in section 3.1. Mutation studies indicate that in particular ECL2 is important for chemokine binding (Figure 10 ). 2 The length and structure of the ECL2 of chemokine receptors is relatively more conserved than for other GPCR subfamilies (e.g., aminergic GPCRs receptors 91 ), which allows the combination of modeling the TM helices and loops as an integrated part of the model construction step 3. There are nevertheless differences in the sequences of the ECL2 of chemokine receptors in length, sequence, and structure. The length of the downstream region from the conserved C 45.50 ECL2 to the start of TM5 is one residue longer in CCR5 than in CXCR4, and it is predicted to be even eight residues longer in ACKR3/CXCR7 compared to CXCR4. Significant differences in the sequence and therefore in the overall structural properties and molecular interaction features of ELC2 can have important effects on ligand binding as has been demonstrated for CCR3, 192 which has an acidic motif (173-ETEELFEET-181) that may explain why ligand binding to this receptor is highly pH dependent. 192 Finally, structural differences in ECL2 between CXCR4 and US28 crystal structures indicate ligand-induced conformational flexibility of this region in chemokine receptors, which has to be properly considered in homology modeling of other chemokine receptor−ligand complexes. As an example of the ligand-induced conformational flexibility of ECL2, a structural superimposition of vMIP-II bound CXCR4 and CX3CL1 bound US28 reveals a clash between the mini-helix of CX3CL1 and CXCR4 ECL2.
Modeling Structural
Interactions between Chemokine Receptors and Intracellular Effectors. The potential bias of the T4L (CXCR4) and rubredoxin (CCR5) fusion proteins and the influence of Nb7 nanobody (US28) should be considered for modeling of the intracellular pocket of chemokine receptors. ICL3 has only been solved in the US28 structure, but the conformation of ICL3 in the US28 structure may be only relevant for the modeling of an active conformation. Of special interest is the modeling of the intracellular pocket for intracellular binding ligands (which will be further described in upcoming sections), as well as for intracellular effectors, including nanobodies, G-proteins, and beta-arrestin, whose main interactions have been described in section 2.2.4. Therefore, for the selection of the most relevant structural template for the modeling of the intracelular pocket, those structures in which this pocket is biased for the presence of stabilizing elements or crystal artifacts should be avoided. There are a few templates to model intracellular effector-bound structures, including complexes between the adrenergic beta-2 receptor and G s protein (PDB 3SN6), 87 the A 2A adenosine receptor and an engineered mini G s protein comprising a truncated GTPase domain of the Gα s subunit (PDB 5G53), 88 bovine rhodopsin and visual arrestin (PDB 4ZWJ), 89 and the C-tail of the vasopressin V 2 receptor and beta-arrestin1 (PDB 4JQI). 193 However, the templates are still limited to specific GPCRs and incomplete (the beta-arrestin1 bound V2 structure only contains the C-tail of the receptor) or do not have a high resolution (the beta-arrestin bound opsin structure has a 7.7 Å resolution). Therefore, modeling of intracellular effectors binding is still challenging and needs more and better templates. However, some models have been already described of chemokine receptors interacting with intracellular effectors. 194 Moreover, important intracellular effectors with no reported GPCR-bound structure are G protein-coupled receptor kinases (GRKs), which are difficult to crystallize due to their flexibility and fast kinetics, being also difficult to model due to their sequence variability. 195 Finally, the available chemokine receptor templates have some characteristics to consider to model intracelular binders: for example, modeling of active conformations may be addressed using US28 structure as template, but it is important to consider also other templates in a fully activated state, especially for modeling a G-protein bound conformation, in which case the ADRB 2 structure may represent a better template. Also the best resolution crystal structure of CXCR4 (PDB 3ODU) lacks H8 and has a nonstructured
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Perspective C-terminal that may affect the modeling of intracellular effector interactions.
Modeling Structural
Interactions between Chemokine Receptors and Small-Molecule Ligands. Predicting the residues that conform the binding pocket is one of the most important steps of the chemokine receptor modeling workflow (step 4, Figure 15 ), especially for those receptors for which no crystal structure has been reported. The availability of experimental data, including site-directed mutagenesis studies, NMRs, or fluorescent measurements, is therefore, important to support the prediction of structural chemokine receptor−ligand interactions. In the GPCR DOCK 2010 challenge, site-directed mutagenesis data 67 , and E 7.39 play a key role in CXCR4 antagonist binding. Although the CXCR4, CCR2, CCR5, CCR9, and US28 X-ray structures provide useful templates for chemokine receptor modeling, binding pocket prediction is still challenging due to the prevalence of multiple potential binding sites in these receptors. For small ligands, it is known that some bind exclusively the minor (CXCR4 antagonist 31) or the major pocket (CXCR4 antagonist CVX15), while others may target both simultaneously (CCR5 antagonist 16). A wide amount of chemokine receptor ligands share a cationic feature (or even two like the CXCR4 antagonist 31), and both the minor and the major pocket have anionic groups with which ligands can interact (residue positions 2.63 and/or 7.39 in the minor pocket, 4.60 and/or 6.58 in the major pocket) as discussed in section 4. The recently solved 29 bound CCR2 and 30 bound CCR9 crystal structures confirm that small-molecule ligands can also target the intracellular binding sites of chemokine receptors, consistent with earlier radioligand binding and mutation studies. 60,61,93,134,146−149 The diversity of different possible binding sites pose a challenges to the prediction of structural chemokine receptor−ligand interactions. Intracellular ligands, including allosteric antagonists of CXCR2 (61−64, Figure 18) , 60 ,61 CCR2 (29, Figure 5, 13) , 15, 134, 146 CCR4, 147,148 CCR5, 147 CCR9 (30, Figure 5, 13) , 16 and CX3CR1 149 combine electronegative H-bond acceptor moieties (to interact with the amide backbone of residue positions 8. 48, 8.49, and 8.50 ) positioned between at least two medium sized aromatic/hydrophobic ring systems (that target different hydrophobic subpockets), and can therefore be distinguished from cationic ligands that target the orthosteric binding site of chemokine receptors. Putative binding regions of novel small-molecule ligands can furthermore be predicted based on integrated SAR and site directed mutagenesis data that is available for similar ligands and/or similar receptors. It should be noted however that the additional, previously unexplored ligand binding sites in chemokine receptors may be accessible, including for example the extracellular vestibule (like the allosteric modulator binding site in the muscarinic M2 receptor crystal 196 ) or the interface with the membrane outlier (e.g., as observed in P2Y1 197 receptor and GCGR 251 crystal structures).
The prediction of the putative ligand binding site(s) is followed by the prediction of ligand binding poses (step 4, Figure 15 ). Molecular docking and pharmacophore tools can generate binding poses for ligands, especially small ligands. 26, 198 The docking of large peptide and protein ligands, including chemokines, increases challenges in sampling of protein−ligand conformations. Poses obtained from docking programs are ranked based on scoring functions. The main challenge in scoring and ranking binding poses is related to the conformation of the side chains in the binding pockets due to rotamer variants.
Priority filters can be used as postprocessing method to prioritize interactions, and MD simulations can be useful to determine the most stable conformations of the residues, as well as of the ligands, to improve the confidence on the protein−ligand interactions. 199 Despite the availability of multiple chemokine receptor crystal structures, symmetry in both the ligand (prevalence of two basic moieties) and the binding site (prevalence of multiple acidic residues) constitute a challenge for the chemokine receptor− ligand binding mode prediction (section 5.3). 77 The evaluation of different putative binding modes of compound 13 in CXCR4 presented in Figure 17 illustrates the caveats of the extrapolation of binding mode information on cocrystallized ligands to other small-molecule ligands and emphasize that structural modeling should be guided and evaluated using experimental data, in line with the GPCR Dock 2010 challenge. 20 Figure 17a shows a docking pose of compound 13 in the minor binding site of CXCR4 with a similar structural interaction fingerprint (IFP) pattern as the cocrystallized ligand 31 (Figure 3a) , whereas Figure 17b presents a docking pose of 13 in the major binding site of CXCR4 that is targeted by CVX15 (Figure 3a) . IFP representation of compound 13 ( Figure 17f ) illustrates common interactions (W94 2.60 , E288 7.39 ) as well as specific interactions derived from the pocket selection of the reference ligand (D97 2.63 for 31, D171
4.60 for CVX15). SAR studies (Figure 17d ) reveal a significantly decrease in affinity if one of the basic amino groups (predicted to interact with D171 4.60 ) is changed to a cyano group, confirming an ionic interaction between the amino group and a negatively charged acidic residue in the binding site. Changing the benzimidazole to a 2-pyridine or 1-tetrahydroisoquinoline is tolerated, consistent with a binding mode in which the basic amine in the benzimidazole group is interacting with an acidic residue (predicted to be E288 7.39 ). The relevance of these acidic residues (D97 2.63 , D171 4.60 , D262 6.58 , and E288 7.39 ) in binding 13 is reflected by mutation studies (Figures 10b and 15b) . 69 Moreover, the length and flexibility of the aliphatic side chain and the stereochemistry of the chiral carbon also affect the potency of compound 13. Both predicted docking poses partially fit the described interactions, but none of them fit all the experimental data, suggesting that these poses may represent different populations of CXCR4−13 conformations or that the docking results should be optimized (Figure 17e ). Optimization includes postprocessing filters, applying restraints on those interactions known to be important for ligand binding and molecular dynamics simulations. 200 Molecular dynamics simulations can be used for the extended sampling of receptor−ligand conformations, the assessment of the relative distribution of different binding mode populations, and the possible role of residues in molecular dissociation and/or association. Despite the challenges that chemokine receptors constitute for molecular modellers, three-dimensional chemokine receptor models have been successfully applied for the identification and design of new chemokine receptor ligands, binding pocket, and ligand binding prediction for CCR5 and CXCR4, 36, 201 and other chemokine  receptors, including CXCR2,  60 CXCR3,  63 CCR1,  50 CCR3,   95 CCR4, 33 and CCR8. 202 Challenges in modeling the binding mode of large chemokine ligands in chemokine receptors subfamily include the consideration of protein flexibility in protein−protein docking and the consideration of alternative binding mode hypotheses to guide the docking process and/or evaluate the docking poses. The vMIP-II bound CXCR4 and CX3CL1 bound US28 crystal structures and reported mutation data indicate that chemokine
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Perspective receptors can accommodate a large variety of chemokine ligand binding modes in different TM subpockets, 13, 14, 111 and the integrated analysis of NMR structures, in silico models, and mutation data indicate multiple binding modes may be possible for the same receptor:chemokine complex. 111, 123, 205 Model evaluation therefore may require complementary in silico approaches and experimental data, such as extensive molecular dynamics simulations and the consideration of combined mutation data of both the receptor and the chemokine ligand. (Figure 18) . 60−62 Mutations in the intracellular region of CXCR2 significantly decreased binding affinity of 61, 62, and 63, whereas the E300 7.39 Q mutant in the extracellular side did not affect binding affinity, supporting an intracellular binding of all three ligands (Figure 18c,d) Figure 18 ). The CXCR2 mutation data indicate that 61, 62, and 63 target a similar binding site as 29 in the CCR2 crystal structure 15 and 30 in the CCR9 crystal structure. 16 The negative effect of the K320 8.49 A mutant, for example, supports a binding mode in which the acidic groups of 61, 62, and 63 ( Figure 18b ) 60 are involved in polar interactions with the positively ionizable K320
8.49 residue and simultaneously Figure 17 . Optimization and evaluation of molecular docking based binding mode prediction studies of compound 13 in CXCR4 using on site-directed mutagenesis 69 and SAR 153, 203, 204 data. (a) Docking pose of 13 in the binding pocket of the 31 bound CXCR4 crystal structure, (c) docking pose in the binding pocket of the CVX15 bound CXCR4 crystal structure, (e) optimized docking pose based on mutation and SAR data. (d) Effects of CXCR4 mutations on the binding affinity of 13, mapped on a helical box diagram (adapted from GPCRdb 49 ). Note that (i) the mutational effect of D262 6.58 (see Figure 11b) is not shown, and (ii) that the helical box of TM2 does not reflect the T 2.56 XP 2.58 kink of chemokine receptors, depicting the residues of 2.60 and 2.63 toward the membrane surface while they are in fact pointing toward the TM binding site. Differences between the pK i values of wild-type and mutant <−0.5 (cyan), −0.5 to 0.5 (blue), 0.5 to 1.0 (yellow), and >1.0 (red) are reported in logarithmic units (annotated data set included in Supporting Information). (d) Summary of structure−activity relationships of analogues of 13. The interactions with key residues derived from mutation studies (gray background) are depicted by a gray dotted line. (f) Comparative structural interaction fingerprint (IFP) analysis of the different binding modes of 13 in CXCR4 presented in panels a, c, and e. The structural receptor−ligand interaction patterns are described by IFP bit strings encoding different interaction types between 13 and the amino acid residues of CXCR4.
Perspective form H-bond interactions with the backbone amide nitrogen of residues R/K (Figure 18a,g) , 61 indicating that this ligand targets the extracellular binding site in CXCR2 and supporting a binding mode in which the imidazole nitrogen of 64 accepts an H-bond from N268
6.52 , while the pyrimidine and imidazole moieties of the ligand may be involved π−π stacking interactions with F130 3.36 and F220 5.47 (Figure 18b,c,f) . CXCR2 therefore represents an experimentally supported example of a chemokine receptor that is targeted by small-molecule modulators that target both extracellular and intracellular binding sites. , and Y308 7.43 (Figures 19d, and 17f ) but also include distinct interaction features supported by ligand-dependent mutation effects. 63 The D112 2.63 N mutation data suggest that the anionic carboxylic acid moiety of D112 2.63 plays a role in binding of 66 but is less important for binding 65 (Figure 19b) . The decreased affinity of 65 for the D186 4.60 N mutant supports a binding mode in which the positively ionizable amine group of 65 forms a salt bridge with the negatively charged D186 4.60 residue. In contrast, the affinity of 66 is not significantly affected by the same D186 4.60 N mutation, suggesting that this residue does not play an important role in binding compound 66 (Figure 19c) . 63 The differential effect of the F131 3.32 A mutant on CXCR3 binding affinity of the chemically similar 68 64 and 66 63 (Figure 19f ) may be explained by subtle differences in substitution pattern of the 
Perspective 4-(trifluoromethoxy)phenyl group of 68 versus the 4-fluoro-3-(trifluoromethyl)phenyl group of 66 that is indeed proposed to target the deep hydrophobic binding site formed by F131 3.32 ( Figure 19d ). CXCR3 mutation studies suggest that D112 2.63 and D186 4.60 are also involved in ionic/H-bond interactions with compound 67 and that also the apolar F135 3.36 residue plays an important role in binding 67. 104 None of the three mutants tested in combination with 19 (Y60 1.39 A, F131 3.32 A, I279
6.59 A) affected CXCR3 binding. 64 The comparative analysis of effects of CCR5 (section 4.2) 56 and CCR2 (section 5.7) 53 mutations on 19 binding affinity may be useful to guide the design of complementary future CXCR3 mutation studies to elucidate the structural determinants of CXCR3 binding by this promiscuous chemokine receptor ligand.
5.7. Structural CCR1−Ligand Interaction Models. For CCR1 about 20 mutation data points have been determined, covering 13 different residue positions (including, among others, Y41
1.39 and Y113 3.32 ) and two different ligands: 69 (BX-471) and 70 (UCB-35625) (Figure 20) . 50, 51 Mutation studies indicated that Y41 play an important role in 69 binding and suggest that the ligand occupies both the minor and major binding pockets. 50 The significant negative effect of the E287 7.39 Q mutant furthermore suggests that this residue is involved in an ionic interaction with the basic piperazine nitrogen atom in the ligand. The binding affinity of 70 is only significantly affected by Y41 1.39 A and Y113 3.32 A mutations in the minor pocket but not by mutations in the major pocket (including Y114 3.33 A, I259 6.55 A, and E287 7.39 Q), 51 suggesting that this ligand primarily targets the minor pocket of CCR1.
5.8. Structural CCR8−Ligand Interaction Models. The effect of a set of 100 mutations on CCR8 potency has been tested for the high-affinity nonpeptide ligand 71 (LMD-009) and its analogues 72 (LMD-584), 73 (LMD-902), 74 (LMD-268), and 75 (LMD-174), including residues Y42
1.39 , Y113 3.32 , and E286 7.39 , among others. 59 These analogues share a common scaffold including a positively charged amino within a piperidinering linked to a biphenyl ether on one side and to a variable group to the other site. The Y42 1.39 A, Y113
3.32 A, or E286 7.39 A mutation data suggest that all four ligands share interactions with the minor pocket of CCR8 (Figure 20b) . 59 The negative effect of the E286 7.39 A mutation supports a ligand binding mode in which the charged amine of the piperidine-ring of 71−75 forms an H-bond and ionic interaction with the carboxylate side chain of E286 7.39 . 
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The differential effects of F254 6.51 A and L257 6.55 A mutants on the potency of 71, 72, 73, 74, and 75 suggest that the variable lefthand side of these ligands (Figure 20b ) is targeting the major pocket.
IN SILICO CHEMOKINE RECEPTOR LIGAND
DISCOVERY AND DESIGN As described in section 5, many challenges have to be overcome in the chemokine receptor modeling process. Despite the inevitable structural inaccuracies of refined chemokine receptor models, they have successfully been used to guide site-directed mutagenesis studies (Figure 11 , 12, 13, 18−20) and design novel chemokine receptor ligands through structure-based in silico methods 24,26−29 ( Figure 22 and Table 1 ). Retrospective virtual screening experiments 24, 38, 208 have been used to validate and select optimal conformations of chemokine receptor homology models by assessing the ability of the model (and in silico screening method) to discriminate known receptor ligands from inactive molecules and/or decoy molecules (randomly selected molecules that have not been experimentally tested on a specific protein target) with similar physicochemical properties. Ligand-based virtual screening (LBVS) has also significantly contributed in identifying new chemokine ligands, as well as other ligand-based approaches including three dimension quantitative structure−activity relationships, 37 ligand-based pharmacophore modeling, 37 similarity search 34 (including shape matching or topological fingerprints), and Bayesian models. 209 However, the current section will focus on prospective structure-based virtual screening (SBVS) studies to find novel chemokine receptor ligands, as well as discuss the challenges and possibilities of SBVS along the different steps of the SBVS workflow ( Figure 21 ). a Only structure-based virtual screening studies targeting the TM domain are included.
b Crystal structure template(s) used to construct the chemokine receptor homology model or cases in which the crystal structure are used are indicated (X-ray).
c Consecutive filters (dl (drug-like physicochemical properties), ll (lead-like physicochemical properties), fl (fragment-like physicochemical properties), 1D (physicochemical properties known ligands), 2D (two-dimensional topological/chemical similarity/pharmacophoric features/subgroups), and 3D (three-dimensional pharmacophore) used to compile database for docking/3D conformer search, MNP marine natural product, NP natural product, GF GPCRfocused library.
d Conformer search method: ((H-bond) constr(ained)) automated docking (ad), protein-based, or docked ligand-based 3D pharmacophore search (3D). 
Prospective validation: initial database (db).
h Number of experimentally confirmed hits with detectable affinity/activity (of the total number of tested compounds). References to homology modeling, virtual screening, and structure-based ligand optimization studies are provided. 24, [27] [28] [29] 37 For the past five years, the first structurebased virtual screening studies against CXCR4 crystal structures, 24 ,26−29 CXCR3, 26 and ACKR3/CXCR7 38 homology models (based on CXCR4 crystal structures) have been reported. Virtual screening hit rates (the percentage of experimentally confirmed ligands among all tested in silico hits) based on chemokine receptor homology models (4%) 24 and the CXCR4 crystal structures (18%) 24, 27 are somewhat lower than the hit rates reported for other GPCRs, 212, 213 including ADRB 2 (24−60%), 214 ,215 DRD 3 (20−40%), 216 A 2A (10−41%), 217, 218 and H 1 R (73%). 219 Moreover, one SBVS study 31 performed against de novo 3D models of five different GPCRs (5-HT 1A , 5-HT 4 , DRD 2 , NK 1 R, and CCR3) yielded hit rates of 12−21% (at a 5 μM cutoff) and several novel nanomolar affinity ligands for 5-HT 1A , 5-HT 4 , DRD 2 , and NK 1 R, but only one low affinity hit (IC 50 = 12 μM) for CCR3.
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Despite the noticeable challenges of in silico discovery of chemokine receptor ligands, therapeutically interesting molecules that modulate chemokine receptors have recently been discovered in structure-based virtual screening campaigns. The binding mode prediction case study of 13 in CXCR4 discussed in section 5.4 ( Figure 17 ) reflects the challenges of binding pocket residues selection, as well as pose selection in docking approaches. Because of ligand fit, residues often show different conformations between structures, even within the same receptor. For example, Y116 
Perspective different conformations in the CVX15 bound CXCR4 structure. These conformational variations of binding site residues poses constitute both a challenge and an opportunity for structurebased virtual screening to identify CXCR4 ligands. 6.2. Hierarchical Workflow for Chemokine Receptor Structure-Based Ligand Discovery. A five-step structurebased virtual screening workflow can be defined customized to identify new ligands for chemokine receptors (Figure 21) . The database preparation step 1 includes prefiltering of the initial compound library (e.g., commercially available compounds in ZINC (http://zinc.docking.org/) 220 ) based on physical−chemical properties (including molecular weight, number of rotatable bonds, rings, hydrogen bond donor/acceptors, positively/ negatively ionizable atoms) in order to select molecules that are, e.g., drug-like, 221 fragment-like, 222, 223 and/or reflect physical−chemical properties of known ligands of a the chemokine receptor target(s). Chemokine receptor ligands are relatively large compared to, e.g,. aminergic receptor ligands 224 and some known chemokine receptor ligands do not pass druglikeness filters such as Lipinski's rule of five (molecular weight <500 Da, <5 H-bond donors, <10 H-bond acceptors, log P < 5). An example is the CXCR4 antagonist 1 ( Figure 11 ) with a molecular weight of 502 Da and 6 H-bond donors. The definition of physical chemical property filters based on known chemokine receptor ligands with high ligand efficiency 225 can be a strategy to focus the virtual screening campaign on the identification of useful chemical starting points for further ligand optimization. An additional chemokine receptor specific filter would be to only consider molecules that contain a positively ionizable group, as this feature is present in most chemokine receptor ligands (Figures 10, 12, 13 , and 17−20) and proposed to target negatively ionizable residues in the binding pocket of chemokine receptors (Figure 1−3 ). An alternative could be to consider only neutral or negatively ionizable molecules that are proposed to interact with the intracellular binding site of chemokine receptors ( Figures 5 and 18) . 14, 60 Challenges in the preparation of threedimensional molecular structures of chemokine receptor focused databases using the physical chemical property and/or pharmacophore filters described above include (i) the definition of correct chemical topology and generation of relevant tautomers and protonation states of molecules containing multiple positively ionizable groups, and (ii) the generation of relevant three-dimensional ring conformations of basic nitrogen containing aliphatic ring systems. Both issues are important for the accurate sampling of ligand conformational space, scoring of receptor−ligand interactions, and definition of protein−ligand interaction fingerprints for docking pose postprocessing. 226 In several virtual screening studies targeting chemokine receptors, additional ligand-based similarity filters have been used for database preprocessing based on substructures, 2D chemical similarity descriptors, 3D-shape similarity, or pharmacophore model features (Table 1) . Shape-based and/or pharmacophore filters can for example be derived from crystal structure bound conformations of compounds 31 (in CXCR4) or 16 (in CCR5) (Figure 3) , from receptor−ligand docking studies (Figure 17) , and/or from ligand-based alignments (Figure 3) . 34, 37 Pharmacophore models compatible with the interaction features of residues that play an important role in ligand binding based on chemokine receptor crystal structures and mutation studies (Figure 11, 12, 13, (18) (19) (20) are predicted to contain 1−2 cationic feature(s) and 1−2 aromatic/hydrophobic feature(s) (Figure 3d ).
In step 2, the database of three-dimensional structures of small molecules is automatically docked into receptor structures/ models, generating and ranking multiple conformations 227 in a predefined binding site. Preparation of the protein for docking simulations includes careful definition of: (i) the binding site that will be targeted in the docking simulation, (ii) the assessment of tautomers and ionization states of receptor residues (i.e., H281 7.32 in CXCR4) considering the interplay with ligand ionization states (e.g., the charged/neutral isothiourea moiety of CXCR ligand 31 interacting with E288 7.39 in CXCR4), (iii) the position of polar hydrogen atoms (e.g., Y37
1.39 in CCR5), (iv) atom typing of cofactors and/or unnatural amino acids (e.g., sY12
N-ter in CXCR4), and (v) the consideration of relevant water molecules that can be targeted and/or displaced (e.g., water molecules 1629, 1646, and 1720 in the 31 bound CXCR4 crystal structure). A possible strategy could be to target only the minor pocket (e.g., defined based on the binding pocket of 31 in the CXCR4 crystal structure), the major pocket (e.g., based on the CVX15 bound CXCR4 structure), the minor and major pocket simultaneously (e.g., based on the 16 bound CCR5 structure), or other putative binding sites (e.g., extracellular vestibule, intracellular region, membrane interface) depending on ligand similarity, mutation data, SAR information, and/or radioligand displacement data.
In step 3, the docking poses are postprocessed and ranked. Most structure-based virtual screening studies targeting chemokine receptors have primarily employed docking scoring functions to rank docking poses (Table 1) , but more and more structure-based in silico screening protocols now include additional filters to postprocess docking results that combine consensus scoring strategies, 228−230 topological filters, (Table 1) . For example, ionic and/or H-bond interactions involving D97 2.63 and E288 7.39 ( Figure 11 ) have been used as a filter for postprocessing docking poses in structure-based virtual screening studies against CXCR4. 24, [26] [27] [28] 36, 234 Crystal structures and mutation studies have identified several key residues that are essential for binding affinity and interactions with these residues, which can be used to define postprocess/filter docking poses: Y45 3.33 , and E286 7.39 for CCR8 ( Figure 20 ). It should be noticed however that the binding mode and role of specific residues can be ligand dependent. It is therefore necessary to perform retrospective virtual screening studies to evaluate the effect of docking pocket definition and postprocessing filter on the possibility to discriminate known ligands from inactive or decoy molecules.
In step 4, the final hits can be selected based on clustering, chemical novelty, visual inspection of the protein−ligand binding mode, and other properties associated with the feasibility
Perspective to optimize the ligand in subsequent medicinal chemistry projects (including drug-likeness (see also step 1 and synthetic tractability). The novelty of the discovered hits can be assessed by a 2D or 3D similarity search against known chemokine receptor ligands. For example, the highest Tanimoto coefficients (Tc) of hits identified in a virtual screening study against CXCR4 24 was 0.36 to the most chemically similar known CXCR4 ligand (at the time of the screen) based on the ECFP-4 chemical fingerprint. 235 Clustering virtual screening hits by chemical diversity before visual selection is an efficient way of analysis when a lot of ligands are retrieved. Furthermore, panassay interference compounds (PAINS) or those that have poor oral bioavailability 221 can be excluded. The CXCR7 virtual screening hit 96 38 for example contains a rhodanine PAINS scaffold (137:ene_five_het_B) which is enriched in highthroughput screening hit sets 236 and has been shown to undergo light-induced reactions that irreversibly modify proteins. 237 Another criteria for the final selection of hits is the visual inspection of docking poses for the detailed analysis of protein− ligand interactions that are challenging to automate and/or score, including for example the analysis of strained ligand conformations, 238 unfavorable protein−ligand interactions such as buried polar groups in hydrophobic pockets, 212, 213 or scoring of specific interactions that are not yet incorporated in most scoring functions, such as halogen bonds. 239 For this purpose, 3D-QSAR models may be used to assist the prioritization of docking poses in a more systematic way. For example, the 3D-QSAR model presented in Figure 3b shows favorable hydrophobic interaction field that can facilitate the prioritization of docking poses of other compounds in the minor pocket of CXCR4. In addition to optimization of protein−ligand interactions, other criteria like protein selectivity (e.g., emphasizing receptor specific interactions and/or incompatibility with offtargets) or synthetic tractability (e.g., consideration of accessible reaction routes, avoiding potential complexity of multiple stereoisomer) can be considered in the final hit prioritization. In most published chemokine receptor structure-based virtual screening studies, a small subset of the compounds is purchased and experimentally validated (step 5, see 76−96 in Figure 22 ). 240 Typically, on the order of 10−100 hits 24,26,27,31−36 are evaluated (though smaller 28, 29, 37 or larger 38 sets have been reported), yielding 1−20 experimentally validated ligands. Structure-based virtual screening hits have been optimized by structure-based design for several GPCRs (e.g., A 2A receptor antagonist, 241, 242 5-HT receptor antagonist, 175 and 5-HT1A agonist 243 ), but so far only few studies 27 have described the structure-based optimization of virtual screening hits for chemokine receptors.
6.3. Prospective VS Targeting Chemokine Receptors. 50 in the high micromolar range. Surprisingly, three molecules were characterized as agonists, illustrating that agonists can also be found by structure-based virtual screening in inactive GPCR models. 233 Another CCR5 virtual screening study conducted by Liu et al. 35 through docking screening (92) and followed by fragment assembly (from the known CCR5 antagonist 16), design, and synthesis resulted in a series of novel small CCR5 antagonists (IC 50 : 0.2−10 μM). Kim et al. 36 performed docking-based virtual screening of 350000 compounds against a de novo CXCR4 model and selected molecules that were docked in close proximity to the acidic residues D171 4.60 , D262 6.58 , and E288 7.39 . One of the 32 experimentally validated virtual screening hits (compound 37, which is chemically similar to the antimalarial drugs chloroquine and hydroxychloroquine) was confirmed as an antagonist of CXCR4-mediated signaling and cell proliferation in pancreatic cancer cells. Perez-Nueno et al. 37, 234 used an optimized and retrospectively validated combination of ligand-based and protein structure-based approaches to design five compounds that were synthesized and experimentally confirmed as CXCR4 ligands (including 87) with anti-HIV activities of 0.022−4.4 μg/mL. Mysinger et al. 24 used the CXCR4 crystal structure and CXCR4 homology models (constructed for the GPCR Dock 2010 Assessment 20 ) in a comparative virtual screening study. In a retrospective validation of their procedure to discriminate 60 actives from 2000 decoys, the crystal structure (28) shows higher enrichment factor (1% of decoys) than the models (the best is 22). Then libraries of >3 million of lead-like compounds were docked against the models and crystal structures. Experimental validation yielded one and four hit compounds (a hit rate of 4% and 17%) from homology models and the crystal structure, respectively (with affinities ranging from 0.31 μM (78) to 225 μM (76)). Das et al. 27 identified a high affinity CXCR4 ligand (81) by combining Tanimoto shape similarity search, docking, and filtering docking poses that made interactions with at least two critical residues (D97 (83) and two antagonists with micromolar potency by CXCR4 crystal structure-based virtual screening of a GPCR focused library of 13000 compounds. 30 Other structure-based virtual screening targeting CXCR4 which focus on natural product databases also resulted in discovering novel CXCR4 ligands such as 82 (PHIA) 28 and 86 (silibinin). 29 
CONCLUSIONS AND OUTLOOK
The CXCR4, CCR2, CCR5, CCR9, and US28 X-ray crystal structures offer useful structural templates for the comparative analysis and prediction of the interactions between chemokine Figure 22 . Representative ligands obtained in structure-based virtual screening (design) studies against chemokine receptors homology models and X-ray structures, including CXCR4 ligands 76, 24 38 Interactions between the ligands and specific residues derived from X-ray structures (bold), mutation studies (gray), or models without support from experimental data (gray italics) are depicted by dotted lines. The affinity or potency values of ligands are reported.
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Perspective receptors and small molecules and large peptide and protein ligands. The integrated analysis of the new structural information on chemokine receptors with extensive structure−activity relationship and site-directed mutagenesis data has facilitated the construction of structural models of chemokine receptor− ligand complexes that have not been crystallized. This experimentally enhanced chemokine receptor modeling strategy helps to overcome the challenges in predicting structural chemokine receptor−ligand interactions. Chemical tools such as smallmolecule radioligands are required to complement integrated structural modeling and mutation studies to accurately characterize the many distinct extracellular and intracellular smallmolecule allosteric binding sites in chemokine receptors and identify other alternative binding sites such as for example the interface of the TM domain and the membrane bilayer, observed in recent GPCR crystal structures. 197, 244 Chemokine bound crystal structures of CXCR4 and US28 share similar binding modes of the chemokine core but lack structural information regarding chemokine interactions with the N-terminal region of the receptor and show different binding modes of the N-terminus of the chemokine in the TM bundle. These differential binding modes are in line with reported chemokine selectivity profiles, ligand dependent mutation effects, and the different conformations of the flexible chemokine N-terminus in X-ray and NMR structures. Specific challenges in modeling chemokine bound structures therefore include: (i) the prediction of interactions with the receptor N-terminus of chemokines, (ii) modeling chemokine binding induced conformational changes of in particular the extracellular loop region, and (iii) describing the dynamics of the flexible binding mode of the N-terminal region of the chemokine in the minor and/or major 7TM binding site(s).
The currently available crystal structures of CXCR4, CCR2, CCR5, CCR9, and US28 provide useful templates to accurately model the TM helical fold, including the chemokine receptor specific T 2.56 XP 2.58 stabilized bulge in TM2, and offer structural model templates with sufficiently high sequence identity to model the TM helices and/or binding sites of other chemokine receptors. More crystal structures of chemokine bound receptor structures will provide new insights into receptor-bound chemokine structural alignment, ELs conformation in a chemokine-bound state, and the bound conformation of N-terminus of the chemokine in the 7TM helical bundle of the receptor. Moreover, it is known that various chemokines can bind more than one chemokine receptor, as well as a receptor can bind more than one different chemokine. 1 More chemokine-bound crystal structures will provide insights into chemokine selectivity/ redundancy because the key interactions that promote chemokine selectivity remain still unknown. However, specific regions have lower similarity to their subfamily reference crystallized chemokine receptors and therefore using as a template the structure of the alternative subfamily should be considered. Although the length of extracellular loops are similar among chemokine receptors, the CXCR4, CCR2, CCR5, CCR9, and US28 crystal structures show that their conformation is influenced by ligand binding, especially by binding of large molecules such as chemokines.
Structure-based ligand discovery and design studies based on chemokine receptor crystal structures and homology models illustrate not only the possibilities but also the challenges to find novel ligands for chemokine receptors. Important pitfalls that have to be addressed in structure-based virtual screening against chemokine receptors are (i) defining an effective scoring method for hit selection and prioritization, (ii) availability of structural data of the receptor, including X-ray, NMR, SAR, and sitedirected mutagenesis data, (iii) existence of multiple and/or allosteric binding pockets in the same receptor, (iv) making enough conformational sampling considering ligands flexibility, and (v) properly preparation of ligands and receptor, especially regarding their protonation state. Structure-based virtual approaches have been successfully applied for chemokine receptors but still require optimization to efficiently address the challenges associated with the symmetric distribution of pharmacophore features in chemokine receptors ligands and the large, open binding sites of chemokine receptors, compared to for example the more druggable, occluded binding sites in aminergic GPCRs. The structural alignment comparison of active US28 vs inactive CXCR4 and CCR5 structures provide clues into the structural features that are significantly representative of active and inactive states. More detailed insights into the structural determinants of functional efficacy of chemokine and small-molecule ligands would, for example, facilitate the rational discovery and design of biased agonists 104 or antagonists 149 by stimulating or inhibiting specific signaling pathways mediated by chemokine receptors. Crystal structures bound to ligands with different functional activities therefore will give new insights that may be used to rationalize interesting structure−function relationships of chemokines 121 and smallmolecule ligands, 245 and may be used to develop customized structure-based virtual screening methods to rationally identify ligands with a specific functional effect, as demonstrated for, e.g., aminergic GPCRs. 246 Whereas the currently available (mini) G-protein and beta-arrestin bound GPCR crystal structures 87−89 provide templates for low resolution modeling of chemokine receptor−transducer interactions, 247 crystal structures of intracellular effector bound chemokine receptors will be required for high resolution investigation of the structural determinants of chemokine receptor mediated signal transduction. Although the CXCR4 crystal structure may represent a possible conformation of a chemokine receptor homodimer, 248 several other GPCR oligomerization models have been proposed, 249 and more information is needed to identify and validate chemokine receptors oligomerization models that are pharmacologically relevant. 250 The recently solved allosteric antagonist bound CCR9 crystal structure and CCR2 chemokine receptor crystal structure simultaneously targeted by orthosteric and allosteric antagonists provide high resolution structural templates to investigate structural interactions with distinct ligand binding pockets in chemokine receptors and will increase our understanding of the interplay between orthosteric and allosteric ligand binding. The accumulated information on the extracellular and intracellular binding sites of chemokine receptors, as well as so far unexploited extrahelical binding sites identified in other GPCRs 197, 251 can open up new possibilities for the computeraided discovery and design of novel chemokine receptor ligands with complementary modes of action. These future developments can include parallel or sequential 252 structure-based virtual screening against multiple binding sites, the design of bitopic ligands that simultaneously target different binding pockets by, e.g., fragment linking approaches, 253 or the structure-based design of bivalent ligands that target different chemokine receptor monomers 254 simultaneously. Moreover, complementing the available structural information with MD simulations may help to reveal ligand association and dissociation pathways and provide insights into the structural determinants of chemokine receptor−ligand binding kinetics. 100, 255 It is expected that
Perspective experimentally enhanced structural modeling of structural chemokine receptor−ligand interactions will provide new insights into complex GPCR structure−function relationships by the computer-aided integration of structural, pharmacological, and chemical information.
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